X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 51.0 49.7 102.7% View Chart
P/BV x 6.9 7.2 95.6% View Chart
Dividend Yield % 0.7 0.5 157.8%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
MERCK LTD
Dec-17
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,5501,358 114.2%   
Low Rs1,144933 122.6%   
Sales per share (Unadj.) Rs354.7665.0 53.3%  
Earnings per share (Unadj.) Rs40.156.6 70.8%  
Cash flow per share (Unadj.) Rs64.272.5 88.6%  
Dividends per share (Unadj.) Rs14.0015.00 93.3%  
Dividend yield (eoy) %1.01.3 79.4%  
Book value per share (Unadj.) Rs273.1441.7 61.8%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.81.7 220.5%   
Avg P/E ratio x33.620.2 166.0%  
P/CF ratio (eoy) x21.015.8 132.7%  
Price / Book Value ratio x4.92.6 190.2%  
Dividend payout %34.926.5 131.8%   
Avg Mkt Cap Rs m227,89719,011 1,198.8%   
No. of employees `00014.71.5 952.1%   
Total wages/salary Rs m11,3531,696 669.2%   
Avg. sales/employee Rs Th4,083.07,150.0 57.1%   
Avg. wages/employee Rs Th772.31,098.7 70.3%   
Avg. net profit/employee Rs Th461.3608.2 75.8%   
INCOME DATA
Net Sales Rs m60,02111,040 543.7%  
Other income Rs m2,988240 1,246.7%   
Total revenues Rs m63,00911,279 558.6%   
Gross profit Rs m13,4931,376 980.4%  
Depreciation Rs m4,086264 1,547.7%   
Interest Rs m3,0850-   
Profit before tax Rs m9,3101,352 688.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m2,529583 433.9%   
Profit after tax Rs m6,781939 722.1%  
Gross profit margin %22.512.5 180.3%  
Effective tax rate %27.243.1 63.0%   
Net profit margin %11.38.5 132.8%  
BALANCE SHEET DATA
Current assets Rs m52,6237,523 699.5%   
Current liabilities Rs m52,0222,253 2,309.4%   
Net working cap to sales %1.047.7 2.1%  
Current ratio x1.03.3 30.3%  
Inventory Days Days12052 229.3%  
Debtors Days Days7641 188.0%  
Net fixed assets Rs m85,0161,240 6,857.8%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m45,3767,167 633.2%   
Net worth Rs m46,2227,333 630.4%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4329,912 1,436.9%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.1 37.8%   
Return on assets %6.99.5 73.1%  
Return on equity %14.712.8 114.6%  
Return on capital %14.220.8 68.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5801,015 1,437.0%   
Fx outflow Rs m3,6003,043 118.3%   
Net fx Rs m10,980-2,028 -541.4%   
CASH FLOW
From Operations Rs m8,942537 1,666.4%  
From Investments Rs m-47,070-476 9,882.3%  
From Financial Activity Rs m34,174-220 -15,547.7%  
Net Cashflow Rs m-3,655-160 2,291.5%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Oil & Gas Stocks Witness Buying(Closing)

Share markets in India ended their trading session marginally higher. Sectoral indices ended on a mixed note with stocks in the energy sector trading in the green.

Related Views on News

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

The Biggest Trend That I'm Seeing in the Market Today(The 5 Minute Wrapup)

Jan 10, 2019

For the first time ever, a majority of Indian households, will start to benefit from stock market wealth.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

A Proven Super Investor Can Lead to Great Wealth(Profit Hunter)

Jan 7, 2019

Following a super investor can certainly help build a portfolio that can create significant wealth in the long term.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 18, 2019 03:37 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS